BiotechTube

Aricept

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cognitive Impairment

Conditions

Cognitive Impairment

Trial Timeline

Feb 1, 2005 → Feb 1, 2007

NCT ID
NCT00103948

About Aricept

Aricept is a phase 2 stage product being developed by Eisai for Cognitive Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT00103948. Target conditions include Cognitive Impairment.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT02158910Pre-clinicalCompleted
NCT00230568ApprovedCompleted
NCT00103948Phase 2Completed
NCT00165815Phase 3Completed

Competing Products

20 competing products in Cognitive Impairment

See all competitors
ProductCompanyStageHype Score
Aricept (donepezil hydrochloride) + placeboEisaiApproved
85
DonepezilEisaiApproved
85
Donanemab + AducanumabEli LillyPhase 3
77
ABT-126 + PlaceboAbbViePhase 2
52
SDI-118 + PlaceboAbbViePhase 1
33
ABT-288 Low Dose + Placebo + ABT-288 High DoseAbbViePhase 2
52
AZD5213 + AZD5213 + AZD5213AstraZenecaPhase 2
52
MK-8931MerckPhase 1
33
Nicotine patch + MK-4334 + Placebo patch + Placebo capsuleMerckPhase 1
33
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)MerckPhase 3
77
RivastigmineNovartisPhase 3
77
RivastigmineNovartisApproved
85
Exelon (rivastigmine) + PlaceboNovartisApproved
85
CanakinumabNovartisPhase 2
52
EvipleraGilead SciencesApproved
84
atorvastatinPfizerPre-clinical
22
bosutinibPfizerPhase 1
32
Aducanumab + PlaceboBiogenPhase 2
49
BIIB080 + BIIB080-matching placeboBiogenPhase 2
49
BIIB104BiogenPhase 2
49

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85